Cellular Immunotherapy for Leukemias—Advances, Limitations, and the Path Forward

Dear Colleagues,

For many years, cytotoxic chemotherapy has been the workhorse in the management of leukemias. Cell lineage-specific antibodies, tyrosine kinase inhibitors, antibody–drug conjugates, apoptosis- or differentiation-targeting drugs, and T–cell redirecting therapies are additional avenues emerging for treating leukemias.  While initial remissions and their depth continue to improve with modern non-cellular pharmacotherapies, relapse prevention/treatment, minimization of consolidation duration, and mitigation of toxicities from various interventions remain an area of unmet need. As genetically modified T cells and allogeneic stem cell transplants make significant strides, our understanding of cells as drugs has grown substantially. However, the question of how best to sequence cellular therapies moving forward requires a comprehensive reexamination of historical gains alongside emerging evidence from registration studies, ongoing clinical trials, and real-world studies.  

This Special Issue seeks to disseminate the advances in cellular immunotherapy for leukemia management. We urge the experts to explore progress and the limitations of cellular therapies to strategically anchor these platforms in next-generation Clinical Trials and Practice Integration.

We look forward to receiving your valuable insights on the pivotal role of cellular immunotherapies in the management of patients with leukemias.

Dr. Lohith Gowda
Prof. Dr. Stuart E. Seropian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.